Ionis Pharmaceuticals shares are trading higher after the company announced results from its phase 1/2 open-label study of Angelman Syndrome, which showed 97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms.
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals shares are trading higher after the company announced positive results from its phase 1/2 open-label study of Angelman Syndrome, showing 97% of patients in the medium and high dose groups saw improvement in symptoms.
July 22, 2024 | 6:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals shares are trading higher following the announcement of positive results from its phase 1/2 study of Angelman Syndrome, with 97% of patients in the medium and high dose groups showing symptom improvement.
The positive results from the phase 1/2 study are likely to boost investor confidence in Ionis Pharmaceuticals' pipeline and its potential to address Angelman Syndrome, leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100